Mrukowicz J Z, Thompson J, Reed G W, Tollefson S J, Kobayashi M, Araki K, Wright P F
Department of Pediatrics, Vanderbilt University, Nashville, TN, USA.
Vaccine. 1999 Feb 26;17(7-8):745-53. doi: 10.1016/s0264-410x(98)00258-8.
This study assessed the frequency of symptomatic and asymptomatic primary and secondary infections with rotavirus in children under 24 months and determined protection against symptomatic illness afforded by rhesus and human-rhesus rotavirus reassortant vaccines. Successive cohorts of children (n 236) were followed through five winter rotavirus seasons with cultures of each reported episode of diarrheal disease and serologic determination of rotavirus exposure on paired sera bracketing the winter. An average of 46% of children experienced rotavirus infection in each season with almost all infected by two years of age. The relative risk of rotavirus associated gastroenteritis in naive children versus naturally immune children was 2.4 (1.1, 5.3). The relative risk of rotavirus associated gastroenteritis in naive children versus vaccinees was 4.1 (1.6, 10.7). In a community with predominantly serotype G1 rotavirus rhesus rotavirus-based vaccines are as protective against rotavirus gastroenteritis as prior natural infection.
本研究评估了24个月以下儿童轮状病毒有症状和无症状的原发性及继发性感染的发生率，并确定了恒河猴和人-恒河猴轮状病毒重组疫苗对有症状疾病的保护作用。连续队列的儿童（n = 236）历经五个冬季轮状病毒流行季节，对每例报告的腹泻病发作进行培养，并对冬季前后配对血清进行轮状病毒暴露的血清学测定。每个季节平均有46%的儿童感染轮状病毒，几乎所有儿童在两岁前都会感染。未感染过轮状病毒的儿童与自然免疫儿童相比，感染轮状病毒相关肠胃炎的相对风险为2.4（1.1，5.3）。未感染过轮状病毒的儿童与接种疫苗儿童相比，感染轮状病毒相关肠胃炎的相对风险为4.1（1.6，10.7）。在以G1血清型轮状病毒为主的社区中，基于恒河猴轮状病毒的疫苗对轮状病毒肠胃炎的保护作用与先前的自然感染相同。
